W0 2011/000721 A1 I||||||||||||||||||||||||||||||||||||||||||||||||||||||||| - Questel

Therefore, there is a need in the field of medicine for new compounds which
are effective in inhibiting infections mediated by immune system lectins,
including DC-SIGN which would be active as well as scarcely cytotoxic.
In addition, langerin is known as a mannose-binding lectin which has been
associated with a protective action against HIV infection. Since langerin is
found in epidermis and mucosa, it is important for topical applications that the
active component shows selectivity for DC-SIGN rather than for langerin.
Accordingly, there is also a need for new compounds which are effective and
highly selective towards DC-SIGN rather than other targets, like langerin.
SUMMARY OF THE INVENTION
The present invention, accordingly, provides new inhibitors of infections, which
do not favour the emergence of resistant strains, has lower toxicity, may be
applied topically and could cross mucoses significantly better compared to the
already known compounds.
In addition, the compounds disclosed in the invention are more selective
towards DC-SIGN than towards other targets, in particular with respect to
langerin.
OBJECT OF THE INVENTION
In a first object, the present invention discloses the antimicrobial compounds of
claims 1 to 12.
In a second object, the present invention concerns a process for the
preparation of the compounds of the invention.
As per a third object, the compounds of the invention are disclosed as a
medicament for the treatment and/or prevention of HIV; Ebola, Dengue,
Hepatitis C, SARS or tuberculosis infections as per claims 13 to 17.